[
    [
        {
            "time": "",
            "original_text": "泰格医药(300347.SZ)截至2月底累计回购约3.1亿元的股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "回购",
                    "3.1亿元"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)截至2月底累计回购约3.1亿元的股份",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【天风医药】泰格医药：全年业绩高增长不变，有望持续受益创新浪潮",
            "features": {
                "keywords": [
                    "泰格医药",
                    "全年业绩",
                    "高增长",
                    "创新浪潮"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药】泰格医药：全年业绩高增长不变，有望持续受益创新浪潮",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "cro行业专题报告:行业转型驱动创仿需求提升,优质cro龙头增长可期",
            "features": {
                "keywords": [
                    "cro行业",
                    "行业转型",
                    "创仿需求",
                    "优质cro龙头",
                    "增长可期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "cro"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "cro行业专题报告:行业转型驱动创仿需求提升,优质cro龙头增长可期",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]